Vertex Pharmaceuticals Inc / Ma
VRTX · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Vertex Pharmaceuticals Inc / Ma at a glance
In FY2025, Vertex Pharmaceuticals Inc / Ma reported revenue of USD 12,001 mn, EBITDA of USD 4,897 mn, EBITDA margin of 40.8%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 11,020 | 12,001 | |||
| EBITDA | 4,602 | 4,897 | |||
| EBITDA margin | 41.8% | 40.8% | |||
| Free cash flow | -790 | 3,194 | |||
| ROIC | — | 107.8% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas